Dose‐Dependent Glycometabolic Effects of Sotagliflozin on Type 1 Diabetes Over 12 Weeks: the inTandem4 Trial

Claire Baker,Suman Wason,Phillip Banks,Sangeeta Sawhney,Anna Chang,Thomas Danne,Diane Gesty‐Palmer,Jake A. Kushner,Darren K. McGuire,Frank Mikell,Mark O'Neill,Anne L. Peters,Paul Strumph

Dose‐Dependent Glycometabolic Effects of Sotagliflozin on Type 1 Diabetes Over 12 Weeks: the inTandem4 Trial

2019

Claire Baker
Suman Wason
Phillip Banks
Sangeeta Sawhney
Anna Chang
Thomas Danne
Diane Gesty‐Palmer
Jake A. Kushner
Darren K. McGuire
Frank Mikell
Mark O'Neill
Anne L. Peters
Paul Strumph

Aims To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D).

Keywords:

Endocrinology
Sotagliflozin
Internal medicine
Diabetes mellitus
Type 1 diabetes
Medicine
Population study
Gastroenterology
Diabetic ketoacidosis
Placebo
Excretion
Postprandial
Insulin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations